Why is argenx stock surging today?

Argenx SE stock experienced a significant 4.0% increase today following the global immunology company's announcement of a definitive agreement to acquire Unnatural Products, Inc. (UNP), a California-based biotech firm specializing in orally-delivered macrocyclic peptides. The potential value of the deal reaches up to approximately $1.15 billion, with $550 million paid upfront and the remainder contingent on development and regulatory milestones.

The acquisition aims to broaden Argent's drug discovery capabilities by integrating UNP's peptide platform, which utilizes AI-guided design, parallel synthesis, and direct-to-biology screening, with Argent's established antibody engineering. This strategic move creates new opportunities for developing oral and long-acting medicines targeting serious immune-mediated diseases.

The transaction is expected to close by year-end, with UNP retaining its team and continuing operations from its Santa Cruz, California site, which will become Argent's peptide discovery hub. While the broader market, represented by the BEL 20 index in Belgium and U.S. markets, remained relatively subdued, Argent's stock outperformed both its domestic index and the healthcare sector, underscoring the company-specific nature of the catalyst.

The acquisition signals Argent's commitment to investing in next-generation science and diversifying its pipeline, reinforcing investor confidence in its strategic direction. Despite trading at €848.2, slightly below its 52-week high of €925, the market views the deal as a credible step towards achieving this goal.